These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 22591662)

  • 1. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
    Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
    Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
    He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
    Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C; Higgins B; Kolinsky K; Xia M; Packman K; Heimbrook DC; Vassilev LT
    Mol Cancer; 2011 May; 10():49. PubMed ID: 21539745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
    Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A
    PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells.
    Ghassemifar S; Mendrysa SM
    Neurosci Lett; 2012 Mar; 513(1):106-10. PubMed ID: 22343310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
    PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.